Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
An attempt was made to produce tumor immunity in 193 patients who had melanoma, 160 of whom had metastases and 33 of whom did not. Four stages of treatment are outlined. The patients whose disease was confined to the skin, subcutaneous tissues, and lymph nodes seemed to benefit most. The treatment was of no benefit to patients whose disease had progressed to the visceral, skeletal, or central nervous systems.
D000912:Antibodies, Neoplasm / Q000032:analysis; D000917:Antibody Formation; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000627:therapeutic use*; D002478:Cells, Cultured; D006801:Humans; D007111:Immunity, Cellular; D008214:Lymphocytes / Q000276:immunology*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D009362:Neoplasm Metastasis; D009439:Neuraminidase; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D009439:Neuraminidase